longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Lipocine

LPCN

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -1.56, within the reasonable range, cheaper than 27.94% of the time in the past 5 years, and the industry ranks 122/257, the industry Median -1.38.

-1.56xP/E
$2.24Stock price
$-1.44Earnings per share
-1.56xP/E
Stock price$2.24Earnings per share$-1.44

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-3.04x
Typical range
-5.76x–-1.25x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0306090120

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-57.15x149.86%$59.68B
BAYZFUSBayer Aktiengesellschaft
-27.33x--$55.15B
BAYRYUSBayer
-27.35x--$55.17B
VTRSUSViatris
-47.82x110.35%$19.64B
ELANUSElanco Animal Health
-56.31x129.36%$11.21B
VREOFUSVIREO GROWTH INC
-165.31x--$11.09B
AXSMUSAxsome Therap
-56.17x27.32%$10.76B
CURLFUSCuraleaf Holdings, Inc.
-153.75x--$8.00B
BLTEUSBelite Bio
-68.22x29.87%$6.98B
DFTXUSDefinium Therapeutics
-14.92x53.32%$5.28B
EWTXUSEdgewise Therapeutics
-24.58x137.29%$4.85B
MANEUSVeraDermics
-45.19x97.44%$4.71B
AMLXUSAmylyx Pharmaceuticals
-26.73x1.76%$4.07B
ELVNUSEnliven Therapeutics
-33.80x1.17%$3.58B
TARSUSTarsus Pharmaceuticals
-73.14x34.09%$3.40B
MBXUSMBX Biosciences
-28.14x30.54%$2.93B
RGCUSRegencell Bioscience
-416.14x--$2.93B
GPCRUSStructure Therapeutics
-12.22x104.48%$2.62B
PHVSUSPharvaris BV
-12.74x7.70%$2.53B
SUPNUSSupernus Pharma
-22.63x70.59%$2.49B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.